| Literature DB >> 23711075 |
Gregory Armstrong, Amenla Nuken, Luke Samson, Shalini Singh, Anthony F Jorm, Michelle Kermode.
Abstract
BACKGROUND: Mental disorders such as depression, anxiety and suicide represent an important public health problem in India. Elsewhere in the world a high prevalence of symptoms of common mental disorders have been found among people who inject drugs (PWID). Research in India has largely overlooked symptoms of common mental disorders among this high risk group. This paper reports on the results of a survey examining quality of life, depression, anxiety and suicidal ideation among adult males who inject drugs living in Delhi.Entities:
Mesh:
Year: 2013 PMID: 23711075 PMCID: PMC3680014 DOI: 10.1186/1471-244X-13-151
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Demographics and substance use (n = 420)
| | |
| 11.3 (7.1-15.6) | |
| 34.4 (28.2-40.6) | |
| 28.7 (23.7-33.6) | |
| 25.6 (19.8-31.4) | |
| | |
| 38.3 (26.7-50.0) | |
| 27.9 (22.2-33.6) | |
| 33.7 (25.2-42.3) | |
| | |
| 74.4 (67.5-81.3) | |
| 6.5 (3.6-9.5) | |
| 4.6 (1.95-7.3) | |
| 4.3 (2.1-6.5) | |
| 10.2 (6.0-14.4) | |
| | |
| 53.3 (46.4-60.1) | |
| 24.6 (17.8-31.4) | |
| 15.5 (12.0-19.0) | |
| 6.6 (3.0-10.2) | |
| | |
| 60.3 (53.7-66.9) | |
| 26.4 (22.0-30.9) | |
| 10.4 (6.3-14.5) | |
| 2.9 (0.6-5.2) | |
| | |
| [smoking, chewing or in paan] | |
| 93.2 (90.1-96.2) | |
| 4.9 (2.3-7.6) | |
| 1.9 (0.5-3.3) | |
| | |
| 21.1 (14.4-27.7) | |
| 43.4 (36.1-50.7) | |
| 9.5 (6.9-12.1) | |
| 19.1 (14.4-23.7) | |
| 7.0 (3.3-10.7) | |
| | |
| ≤ | 34.1 (29.1-39.0) |
| 26.2 (21.6-30.8) | |
| 18.3 (13.7-22.9) | |
| 21.5 (15.9-27.1) | |
| | |
| 99.0 (98.1-100.0) | |
| 97.4 (95.4-99.3) | |
| 76.6 (69.9-83.3) | |
| 73.0 (63.4-82.7) | |
| 53.0 (44.8-61.1) | |
| 42.3 (35.6-48.9) | |
| 26.5 (19.1-33.9) | |
| 25.1 (19.6-30.6) | |
| 22.2 (17.1-27.4) | |
| | |
| 76.9 (69.7-84.1) | |
| 18.0 (11.6-24.3) | |
| 5.2 (1.7-8.6) | |
| | |
| ≤ | 14.4 (10.4-18.3) |
| 28.7 (23.0-34.3) | |
| 36.4 (30.9-42.0) | |
| 20.5 (15.5-25.5) |
a Buprenorphine, heroin, morphine, pentazocine (common brand name is Fortwin) and Spasmoproxyvon are synthetic opioid analgesics. Spasmoproxyvon is the brand name for a compound drug containing dextropropoxyphene, dicyclomine hydrochloride and paracetamol. Pheniramine maleate (common brand name is Avil) and promethazine (common brand name is Phenergan) are antihistamines.
b Both buprenorphine and heroin are commonly injected in a cocktail combination with a liquid antihistamine and often diazepam as well.
Quality of life and socio-economic indicators (n = 420)
| | |
| 21.1 (15.5-26.7) | |
| 60.0 (55.5-64.4) | |
| 19.0 (14.4-23.5) | |
| | |
| [safe from violence, crime and harassment] | |
| 17.7 (13.0-22.4) | |
| 54.2 (47.6-60.7) | |
| 28.2 (21.8-34.6) | |
| | |
| 0.7 (0.0-1.4) | |
| 10.9 (7.3-14.6) | |
| 45.9 (40.7-51.2) | |
| 26.8 (22.1-31.4) | |
| 15.6 (10.3-20.9) | |
| | |
| 3.0 (1.1-5.0) | |
| 13.5 (9.8-17.2) | |
| 43.0 (37.7-48.4) | |
| 21.3 (15.5-27.1) | |
| 19.2 (13.0-25.3) | |
| | |
| 16.4 (9.6-23.2) | |
| 11.1 (7.8-14.3) | |
| 27.1 (22.9-31.3) | |
| 45.4 (38.4-52.5) | |
| | |
| 37.8 (56.7-67.6) | |
| 62.2 (56.7-67.6) | |
| | |
| 38.0 (32.7-43.3) | |
| 28.0 (22.9-33.2) | |
| 32.1 (27.4-36.8) | |
| 1.8 (0.6-3.1) | |
| | |
| ≤ | 21.9 (16.7-27.1) |
| 26.8 (21.7-32.0) | |
| 24.3 (19.8-28.8) | |
| 11.9 (7.8-16.0) | |
| 15.1 (10.7-19.6) | |
| | |
| 10.9 (6.3-15.5) | |
| 18.7 (11.7-25.8) | |
| 47.8 (37.5-58.2) | |
| 1.8 (0.5-3.2) | |
| 5.7 (2.4-9.0) | |
| 1.7 (0.1-3.3) | |
| 11.1 (7.1-15.1) | |
| 2.2 (0.1-3.9) | |
| | |
| 68.8 (57.4-80.3) | |
| 16.0 (8.6-23.4) | |
| 5.9 (1.6-10.2) | |
| 5.7 (3.1-8.2) | |
| 3.6 (1.8-5.3) | |
| | |
| 30.4 (27.2-33.5) | |
| 69.6 (66.5-72.8) | |
| | |
| 50.7 (44.5-57.0) | |
| 1 | 15.7 (10.6-20.9) |
| 13.2 (9.5-16.9) | |
| 9.3 (6.4-12.1) | |
| 11.0 (8.4-13.5) |
a 1.00 USD = 54.25 rupees [as of 9th May 2013].
Prevalence of recent symptoms of depression and anxiety, and 12-month prevalence of suicidal ideation (n = 420)
| PHQ-9 score: average | 14.66 (13.68-5.65) |
| GAD-2 score: average | 3.44 (3.20-3.68) |
| PHQ-9 score: ≥10 | 84.4 (79.6-89.2) |
| PHQ-9 score: ≥15 | 54.2 (45.4-63.0) |
| PHQ-9 score: ≥20 | 17.4 (10.7-24.1) |
| GAD-2 score: ≥3 | 70.5 (64.3-76.8) |
| Have you thought about killing yourself in the past 12 months? | |
| 46.9 (41.9-52.0) | |
| 53.1 (48.0-58.1) | |
| How often have you thought about killing yourself in the past 12 months? | |
| 46.9 (41.9-52.0) | |
| 8.8 (5.4-12.2) | |
| 22.1 (18.1-26.1) | |
| 15.1 (11.0-19.3) | |
| 7.0 (4.2-9.9) | |
| Have you ever made a plan to kill yourself in the past 12 months? | |
| 66.3 (61.4-71.2) | |
| 33.7 (28.8-38.6) | |
| Have you ever attempted to kill yourself in the past 12 months? | |
| 63.8 (58.6-68.9) | |
| 36.3 (31.1-41.4) | |
Note: PHQ-9 scores of ≥10, ≥15 and ≥20 represent cut points for moderate, moderately severe and severe depression symptomology. A GAD-2 score of ≥3 represents the optimum cut point when screening for anxiety.